of distribution for amikacin shows enormous variation among the populations of patients requiring aminoglycoside therapy for severe infections. Although it seems advisable to monitor amikacin blood levels the peak and trough levels which should be achieved for optimal efficacy and minimal toxicity for the once daily regimen remain to be determined. Pending further clinical evaluation it seems reasonable to avoid trough levels higher than 5 mg/1 (for amikacin) or 2 mg/1 (for other aminoglycosides). Animal models have demonstrated that renal uptake of gentamicin, netilmicin and amikacin, but not that of tobramycin, do not correlate linearly with serum concentrations (Guiliano et al., 1986; Verpooten et al., 1989; De Broe, Verbist & Verpooten, 1991) . Relatively less of the former three aminoglycosides accumulate in the kidney with increases in serum concentrations. It is likely that this observation may explain the lesser nephrotoxicity observed with once-daily regimens, compared to divided daily dosings, as demonstrated in various animal models (Frame et al., 1977; Reiner, Bloxham & Thompson, 1978; Powell et al., 1983) .
Toxicity is an important issue in the debate over once daily dosing. In patients treated with netilmicin, the once-daily regimen delayed the occurrence of nephrotoxicity in comparison with multiple daily dosing (ter Braak et al., 1990) . Of the five studies dealing with more than 700 paediatric and adult patients, using the conventional regimen as control, less nephrotoxicity was observed with the once-daily dosing regimen in one study (P. E. Marik, personal communication), a second study supported the same trend (using phospholipiduria as the criterion; Tulkens, 1991) , while the three other studies failed to indicate a significant difference (Giamarellou et al., 1991; Mailer et al., 1991; S. Lauwers, personal communication) . However, in considering aminoglycoside toxicity ototoxicity is also extremely important, since severe irreversible damage can occur, including deafness. Comparative studies are extremely difficult to perform and interpret because baseline auditory function is rarely defined in the severely ill patient requiring aminoglycoside therapy. Furthermore the mechanisms of aminoglycoside ototoxicity remain unclear; aminoglycoside induced inner ear defects do not seem to be associated with drug accumulation as in the case of nephrotoxicity (Tran Ba Huy, Bernard & Schacht, 1981) . However, in a population of young females suffering from pelvic inflammatory disease and without other serious underlying disease, surveillance by high tone audiometry showed a significant safety advantage with the once-daily regimen compared to the divided daily schedules of netilmicin (Tulkens, 1991) .
Clinical evaluation of dosing schedules of aminoglycosides with respect to efficacy is difficult largely because these antibiotics are generally prescribed in combination with other agents. Four controlled, randomized, open studies are presented in this issue of the Journal. These patients had various infectious conditions mainly caused by Gram-negative bacilli, and were most often treated with amikacin plus a /Mactam. One study favoured once daily dosing (Giamarellou et al., 1991) , while the others indicated similar efficacy of the two regimens Tulkens, 1991; S. Lauwers, personal communication) . Other studies, conducted with netilmicin also showed similar efficacy (Fan et al, 1988; Hollender et al., 1989) . In patients with neutropenia and various immunodeficiencies, studies published to date are inadequate to assess the efficacy of the once-daily dosing regimen. A large, randomized, controlled study comparing amikacin and ceftriaxone (once daily) with amikacin and ceftazidime (divided dosing) conducted by the European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative group is awaited with interest.
In conclusion in non-neutropenic patients with proven or suspected Gram-negative infections for which an aminoglycoside seems appropriate, once daily dosing deserves serious consideration; studies suggest it to be at least as efficacious and as safe as conventional dosing regimens. The new regimen has the obvious advantage of greater convenience, more acceptable to patients, and economic advantages. With regard to neutropenic patients, the results of on-going studies should be awaited before firm conclusions can be made.
